Latest Content

Exercise Improves Survival End Points After High-Risk CRC Treatment

June 2nd 2025, 3:00pm

By Ryan Scott

Article

Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage 3 and high-risk stage 2 CRC.

Breaking Down the CheckMate 901 Trial Data for Metastatic Bladder Cancer

June 2nd 2025, 2:00pm

By Dr. Guru Sonpavde

Article

Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.

Imfinzi Combo Boosts Survival in Resectable Gastric and GEJ Cancer

June 2nd 2025, 1:46pm

By Chris Ryan

Article

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer.

Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer

June 1st 2025, 12:00pm

By Tony Berberabe

Article

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

Camizestrant and CDK4/6 Inhibition Benefits Outcomes in Breast Cancer Subgroups

June 1st 2025, 12:00pm

By Caroline Seymour

Article

Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer.

Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer

June 1st 2025, 12:00pm

By Ariana Pelosci

Article

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.

Trodelvy/Keytruda Extends PFS Versus Chemo/Keytruda in PD -L1+ TNBC

May 31st 2025, 12:10pm

By Kristi Rosa

Article

Trodelvy plus Keytruda, when given in the frontline, extended survival without progression versus chemo plus Keytruda in PD-L1+ metastatic TNBC.

Enhertu Improves Survival End Points Vs Cyramza/Paclitaxel in HER2+ GC/GEJ

May 31st 2025, 12:05pm

By Tim Cortese

Article

Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma.

Vepdegestrant Boosts Outcomes in ESR1-Mutant ER+/HER2– Advanced Breast Cancer

May 31st 2025, 12:00pm

By Caroline Seymour

Article

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when compared with Faslodex.

Rapid Developments to Enhance Patient Experience in GU Cancer

May 30th 2025, 9:00pm

By Dr. John L. Gore

Article

New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while personalizing patient outcomes.

Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes

May 30th 2025, 7:00pm

By Alex Biese

Article

Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.

The Healing Power of Teddy Bears for Adults With Cancer

May 30th 2025, 5:00pm

By Chester Freeman

Article

There are many instances where teddy bears can be the key to opening hearts and minds during cancer care.

First Patient Treated in Second Cohort of STARLIGHT-1 B-Cell NHL Trial

May 30th 2025, 3:00pm

By Ryan Scott

Article

The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.

Antidepressants May Boost Antitumor Immunity

May 30th 2025, 1:00pm

By Spencer Feldman

Article

Blocking serotonin transporters with antidepressants boosted CD8 T cell function and enhanced immunotherapy response in mouse and human tumor models.

Braftovi and Erbitux Plus Chemo Improves Outcomes for BRAF V600E+ mCRC

May 30th 2025, 12:00pm

By Chris Ryan

Article

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting.